Advertisement

Drugs & Aging

, Volume 13, Issue 2, pp 173–180 | Cite as

Repaglinide

  • Julia A. Balfour
  • Diana Faulds
Adis New Drug Profile

Abstract

  • ▲ Repaglinide is a novel insulin secretagogue being developed for the management of type 2 (non-insulin-dependent) diabetes mellitus. It stimulates release of insulin from the pancreatic β-cell, but appears to bind to a different receptor site from sulphonylureas.

  • ▲ Repaglinide lowers fasting and postprandial blood glucose levels in animals, healthy volunteers and patients with type 2 diabetes mellitus.

  • ▲ Repaglinide is rapidly absorbed and eliminated, which may allow a relatively fast onset and offset of action. Excretion occurs almost entirely by non-renal mechanisms.

  • ▲ In comparative clinical trials in patients with type 2 diabetes mellitus, repaglinide 0.5 to 4mg twice or 3 times daily before meals provided similar glycaemic control to glibenclamide (glyburide) 2.5 to 15 mg/day. Addition of repaglinide to existing metformin therapy resulted in improved glycaemic control.

  • ▲ In contrast with glibenclamide, use of repaglinide allowed patients to miss a meal without apparently increasing the risk of hypoglycaemia.

Keywords

Metformin Adis International Limited Glibenclamide Repaglinide Glimepiride 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Gromada J, Dissing S, Kofod H, et al. Effects of the hypoglycaemic drugs repaglinide and glibenclamide on ATP-sensitive potassium-channels and cytosolic calcium levels in beta TC3 cells and rat pancreatic beta cells. Diabetologia 1995 Sep; 38: 1025–32PubMedCrossRefGoogle Scholar
  2. 2.
    Van Onderbergen A, Malaisse LF, Malaisse WJ. Failure of meglitinide analogues to augment Ba(2+)-induced insulin release. Med Sci Res 1995; 23 (6): 371–2Google Scholar
  3. 3.
    Fuhlendorff J, Rorsman P, Kofod H, et al. Stimulation of insulin release by repaglinide and glibenclamide involves both common and distinct processes. Diabetes 1998; 47: 345–51PubMedCrossRefGoogle Scholar
  4. 4.
    Malaisse WJ. Insulinotropic action of meglitinide analogues: modulation by an activator of ATP-sensitive K+ channels and high extracellular K+ concentrations. Pharmacol Res 1995 Sep; 32: 111–4PubMedCrossRefGoogle Scholar
  5. 5.
    Fuhlendorff J, Carr R, Kofod H, et al. The mechanism of action of repaglinide differs to sulphonylureas in murine beta cells [abstract]. Pharmacol Res 1995; 31 Suppl. 1.: 32CrossRefGoogle Scholar
  6. 6.
    Fuhlendorff J, Carr RD, Kofod H. Repaglinide: unique mechanism of action in normal and metabolic stressed β cells [abstract]. Diabetologia 1995; 38 Suppl. 1: A195Google Scholar
  7. 7.
    Viñambres C, Villanueva-Peñacarrillo ML, Valverde I, et al. Repaglinide preserves nutrient-stimulated biosynthetic activity in rat pancreatic islets. Pharmacol Res 1996 Jul–Aug; 34: 83–5PubMedCrossRefGoogle Scholar
  8. 8.
    Ladrière L, Malaisse-Lagae F, Fuhlendorff J, et al. Repaglinide, glibenclamide and glimepiride administration to normal and hereditarily diabetic rats. Eur J Pharmacol 1997 Sep 24; 335: 227–34PubMedCrossRefGoogle Scholar
  9. 9.
    Mark M, Grell W. Hypoglycaemic effects of the novel antidiabetic agent repaglinide in rats and dogs. Br J Pharmacol 1997 Aug; 121: 1597–604PubMedCrossRefGoogle Scholar
  10. 10.
    Robling MR, Dolben J, Luzio SD. Single dose-response study of a new oral hypoglycaemic agent in diet-treated patients with non-insulin-dependent diabetes mellitus (NIDDM) [abstract]. Br J Clin Pharmacol 1992 Aug; 34: 173PGoogle Scholar
  11. 11.
    Schwartz SL, Goldberg RB, Strange P. Repaglinide in type 2 diabetes: a randomized, double-blind, placebo-controlled, dose-response study [abstract no. 0382]. Diabetes 1998; 47: A98CrossRefGoogle Scholar
  12. 12.
    Hedberg TG. Repaglinide: a double-blind, randomised, dose-response study. Abstract submitted to the 34th Annual Meeting of the- European Association for the Study of Diabetes; 1998 Sep 8–12: BarcelonaGoogle Scholar
  13. 13.
    Profozic V, Babic D, Renar I, et al. Benzoic acid derivative hypoglycaemic activity and pharmacokinetics in non-insulin dependent diabetic patients. Diab Croatica 1996; 25: 109–16Google Scholar
  14. 14.
    Ampudia-Blasco FJ, Heinemann L, Bender R, et al. Comparative dose-related time-action profiles of glibenclamide and a new non-sulphonylurea drug, AG-EE 623 ZW, during euglycaemic clamp in healthy subjects. Diabetologia 1994 Jul; 37: 703–7PubMedCrossRefGoogle Scholar
  15. 15.
    Oliver S, Windfeld K, Hatorp V. Pharmacokinetics and bioavailability of repaglinide, a new OHA for patients with NIDDM [abstract]. Diabetes 1997 May; 46 Suppl. 1: 331AGoogle Scholar
  16. 16.
    Hatorp V, Nielsen KK, Rathgen K, et al. Bioavailability of repaglinide after administration as either 2 mg tablet or 2 mg i.v. infusion [abstract]. J Clin Pharmacol 1997 Sep; 37: 874Google Scholar
  17. 17.
    Hatorp V, Bayer T. Repaglinide bioavailability in the fed or fasting state [abstract]. J Clin Pharmacol 1997 Sep; 37: 875Google Scholar
  18. 18.
    Perentesis GP, Damsbo P, Müller PG, et al. Single dose pharmacokinetics and pharmacodynamics of repaglinide in type II diabetic patients [abstract]. J Clin Pharmacol 1994 Oct; 34: 1021Google Scholar
  19. 19.
    Schwartz SL, Strange P. Repaglinide does not accumulate in patients with type 2 diabetes [abstract no. 1380]. Diabetes 1998; 47 Suppl. 1: A357Google Scholar
  20. 20.
    Van Heiningen PNM, Hatorp V, Van Lier JJ, et al. Disposition of one dose of 14C-repaglinide during non-labeled repaglinide multiple dosing [abstract no. 1374]. Diabetes 1998; 47 Suppl. 1: A355Google Scholar
  21. 21.
    Bauer E, Beschke K, Ebner T, et al. Biotransformation of [14C]repaglinide in human, cynomolgus monkey, dog, rabbit, rat and mouse [abstract]. Diabetologia 1997 Jun; 40 Suppl. 1: 326Google Scholar
  22. 22.
    Marbury TC, Hatorp V. Pharmacokinetics of repaglinide after single and multiple doses in patients with renal impairment compared with normal healthy volunteers [abstract no. 1381]. Diabetes 1998; 47 Suppl. 1: A357Google Scholar
  23. 23.
    Hatorp V, Haug-Pihale G. A comparison of the pharmacokinetics of repaglinide in healthy sujects with that in subjects with chronic liver disease [abstract no. 1375]. Diabetes 1998; 47 Suppl. 1: A356Google Scholar
  24. 24.
    Wolffenbuttel BHR, Nijst L, Sels JPJE, et al. Effects of a new oral hypoglycaemic agent, repaglinide, on metabolic control in sulphonylurea-treated patients with NIDDM. Eur J Clin Pharmacol 1993; 45 (2): 113–6PubMedCrossRefGoogle Scholar
  25. 25.
    Landgraf R, Bilo H. Repaglinide vs glibenclamide: a 14-week efficacy and safety comparison [abstract]. Diabetes 1997 May; 46 Suppl. 1: 162AGoogle Scholar
  26. 26.
    Marbury TC, Strange P. Multicenter, randomized comparison of the therapeutic effects of long-term use of repaglinide with glyburide in type 2 diabetes [abstract no. 0292]. Diabetes 1998; 47 Suppl. 1: A75Google Scholar
  27. 27.
    Goldberg RB, Brodows RG, Damsbo P. A randomized, placebo-controlled trial of repaglinide in the treatment of type 2 diabetes [abstract no. 0383]. Diabetes 1998; 47 Suppl. 1: A98Google Scholar
  28. 28.
    Van Gaal LF, Van Acker KL, Damsbo P, et al. Metabolic effects of repaglinide, a new oral hypoglycaemic agent in therapy-naive type 2 diabetics [abstract]. Diabetologia 1995; 38 Suppl. 1: A43Google Scholar
  29. 29.
    Damsbo P, Andersen PH, Lund S, et al. Improved glycaemic control with repaglinide in NIDDM with 3 times daily meal related dosing [abstract]. Diabetes 1997 May; 46 Suppl. 1: 34AGoogle Scholar
  30. 30.
    Tronier B, Marbury TC, Damsbo P, et al. A new oral hypoglycaemic agent, repaglinide minimises risk of hypoglycaemia in well controlled type 2 diabetic patients [abstract]. Diabetes 1995 May; 44 Suppl. 1: 70AGoogle Scholar
  31. 31.
    Moses R, Slobodniuk R, Donnelly T, et al. Additional treatment with repaglinide provides significant improvement in glycaemic control in NIDDM patients poorly controlled on metformin [abstract]. Diabetes 1997 May; 46 Suppl. 1: 93Google Scholar
  32. 32.
    Damsbo P, Perentesis G, Müller PG, et al. Favorable tolerability profile of repaglinide in NIDDM after multiple ascending doses [abstract]. J Clin Pharmacol 1997 Sep; 37: 875Google Scholar

Copyright information

© Adis International Limited 1998

Authors and Affiliations

  1. 1.Adis International LimitedMairangi Bay, Auckland 10New Zealand

Personalised recommendations